Publication:
What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?

dc.contributor.authorBakırcı, Sibel
dc.contributor.authorSolmaz, Dilek
dc.contributor.authorAl Osaimi, Noura
dc.contributor.authorCan, Meryem
dc.contributor.authorErden, Abdulsamed
dc.contributor.authorÖzişler, C.
dc.contributor.authorÇınar, Muhammet
dc.contributor.authorKılıç, Levent
dc.contributor.authorKüçük, A.
dc.contributor.authorOmma, Ahmet
dc.contributor.authorYıldız, Fatih
dc.contributor.authorDoğru, Atalay
dc.contributor.authorEsmen, Serpil Ergülü
dc.contributor.authorAkar, Servet
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorAydın, Sibel Zehra
dc.contributor.authorTufan, Abdurrahman
dc.contributor.buuauthorDalkılıç, Ediz
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.departmentRomatoloji Bilim Dalı
dc.contributor.researcheridCMF-4757-2022
dc.contributor.scopusid6506739457
dc.date.accessioned2024-02-06T12:18:25Z
dc.date.available2024-02-06T12:18:25Z
dc.date.issued2019-09
dc.description.abstractObjective: Minimal disease activity (MDA) is an important target in patients with psoriatic arthritis (PsA), however it is also criticised for having a low threshold for patient reported outcomes (PRO). The aim of the study was to assess the prevalence of MDA and its components in patients with PsA and to evaluate disease characteristics and patterns in patients with or without MDA (MDA(+) or MDA(-)).MethodsPsArt-ID (Psoriatic Arthritis-International Database) is a prospective, multicentre web-based registry. PsA patients who had at least 1 year of disease duration and had full data for MDA were included for this analysis (n=317). Patients were considered in MDA+ when they met at least 5/7 of the MDA criteria.ResultsMDA was achieved in 46% patients. Within MDA- patients, body surface area (51.2%) and swollen joint count (53.5%) domains could still be achieved in the majority and 93.5% of them had no enthesitis using the Leeds enthesitis index. Of 170 patients with MDA-, 90 patients did not fulfill all 3 PROs of MDA. Mono-arthritis subtype (RR: 2.01), absence of enthesitis (RR: 1.570) and absence of distal interphalangeal (DIP) joint disease (RR: 1.1) were associated with higher probability of achieving MDA.ConclusionThe MDA criteria provide an objective target for treatment in trials and clinical practice; however, in real life PROs are the most significant barriers to achieve MDA. The presence of DIP joints disease makes it difficult to reach MDA due to active PROs.
dc.description.sponsorshipTürk Romatoloji Derneği (TRD)
dc.description.sponsorshipUnion Chimique Belge (UCB)
dc.identifier.citationBakırcı, S. vd. (2019). "What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?". Clinical and Experimental Rheumatology, 37(5), 808-812.
dc.identifier.eissn1593-098X
dc.identifier.endpage812
dc.identifier.issn0392-856X
dc.identifier.issue5
dc.identifier.pubmed30767863
dc.identifier.scopus2-s2.0-85072349561
dc.identifier.startpage808
dc.identifier.urihttps://europepmc.org/article/med/30767863
dc.identifier.urihttps://hdl.handle.net/11452/39565
dc.identifier.volume35
dc.identifier.wos000485817300014
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherClinical & Exper Rheumatology
dc.relation.collaborationYurt içi
dc.relation.collaborationYurt dışı
dc.relation.collaborationSanayi
dc.relation.journalClinical & Exper Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.relation.tubitakTÜBİTAK
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPsoriatic arthritis
dc.subjectMinimal disease activity
dc.subjectPatient-reported outcomes
dc.subjectPredictors
dc.subjectCriteria
dc.subjectRheumatology
dc.subjectPsoriasis
dc.subject.emtreeAntirheumatic agent
dc.subject.emtreeBiological product
dc.subject.emtreeDisease exacerbation
dc.subject.emtreeHuman
dc.subject.emtreeProspective study
dc.subject.emtreePsoriatic arthritis
dc.subject.emtreeRemission
dc.subject.emtreeSeverity of illness index
dc.subject.emtreeTreatment outcome
dc.subject.meshAntirheumatic agents
dc.subject.meshArthritis, psoriatic
dc.subject.meshBiological products
dc.subject.meshDisease progression
dc.subject.meshHumans
dc.subject.meshProspective studies
dc.subject.meshRemission induction
dc.subject.meshSeverity of illness index
dc.subject.meshTreatment outcome
dc.subject.scopusPustulosis Palmoplantaris; Secukinumab; Nail Diseases
dc.subject.wosRheumatology
dc.titleWhat are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?
dc.typeArticle
dc.wos.quartileQ2 (Rheumatology)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı/Romatoloji Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: